External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

By Michel Bolla, G. van Tienhoven, P. Warde, J. Dubois, R. Mirimanoff, G. Storme, J. Bernier, A. Kuten, C. Sternberg, I. Billiet and 5 more. The Lancet Oncology, 2010

913 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Urology

View Paper: https://www.semanticscholar.org/paper/5f837ead3a0e05373ad133d689149fa13032cf0e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. N. Mottet
2. Thomas Wiegel

Citations in the corpus

• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. (2020, background): “The standard of care for patients with T3 – 4 N0, M0 locally advanced PCa is IMRT combined with long-term ADT for at least 2 – 3 yr, as it results in better OS [158 – 160].”
• EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. (2024, neutral): “For patients treated with RT, OS and disease-free survival were significantly better with additional adjuvant ADT for 3 yr [139].”